 EAST SETAUKET, NY, Jan. 19, 2021 GLOBE NEWSWIRE -- Lixte Biotechnology Holdings, Inc . NASDAQ: LIXT, a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced an agreement on a Phase 1b clinical trial with City of Hope , a world-renowned independent cancer research and treatment center. The trial will assess the combination of Lixtes first-in-class protein phosphatase inhibitor LB-100 with a standard regimen for untreated, extensive stage-disease small cell lung cancer ED-SCLC. 